Migraine Treatment Optimization Questionnaire-4 (mTOQ-4)
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Very Poor0–0
- Poor1–5
- Moderate6–7
- Maximum8–8
The Migraine Treatment Optimization Questionnaire-4 (mTOQ-4) calculates quantifying neurological deficit severity, stroke volume, and reperfusion therapy eligibility. Key inputs include pain free 2 hours. Scores guide initiating intravenous thrombolysis, activating endovascular thrombectomy pathways, or secondary prevention protocols. This standardized assessment improves clinical decision safety and bedside patient management.
Clinical Guidelines & Evidence
Determines effectiveness of current migraine treatment plan to guide treatment optimization decisions
Clinical Indication
The Migraine Treatment Optimization Questionnaire-4 (mTOQ-4) is indicated for bedside clinical practice to support Determines effectiveness of current migraine treatment plan to guide treatment optimization decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with acute neurological deficits, acute ischemic stroke, intracranial hemorrhage, seizures, or altered mental status. Clinical application is indicated across Comprehensive stroke centers, acute neurovascular units, neuro-ICU, and emergency neurology services.
Limitations & Contraindications
Stroke mimics including severe hypoglycemia, Todd postictal paresis, and hemiplegic migraine must be ruled out prior to intravenous thrombolysis.
Clinical Pearls & Action Plan
Time is brain; rapid determination of Last Known Well time and baseline functional status dictates reperfusion eligibility. Guideline pearl: Higher scores indicate better treatment optimization and lower risk of chronic migraine.
mTOQ-4 Score = Q1 + Q2 + Q3 + Q4 (where 0=never/rarely, 1=less than half the time, 2=half the time or more)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| pain_free_2_hours | string | Yes | After taking your migraine medication, are you pain-free within 2 hours for most attacks? |
| relief_24_hours | string | Yes | Does 1 dose of your migraine medication usually relieve your headache and keep it away for at least 24 hours? |
| able_to_plan | string | Yes | Are you comfortable enough with your migraine medication to be able to plan your daily activities? |
| feel_in_control | string | Yes | After taking your migraine medication, do you feel in control of your migraines enough so that you feel you can return to normal function? |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 0–0 | Very Poor | Very poor treatment efficacy |
| 1–5 | Poor | Poor treatment efficacy |
| 6–7 | Moderate | Moderate treatment efficacy |
| 8–8 | Maximum | Maximum treatment efficacy |
Evidence-Based References (EBM)
- Lipton RB, Kolodner K, Bigal ME, Valade D, Láinez MJ, Pascual J, et al. Validity and reliability of the migraine-treatment optimization questionnaire. Cephalalgia. 2009 Jul;29(7):751-9. doi: 10.1111/j.1468-2982.2008.01786.x.DOI: 10.1111/j.1468-2982.2008.01786.x
- Lipton RB, Fanning KM, Serrano D, Reed ML, Cady R, Buse DC. Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine. Neurology. 2015 Feb 17;84(7):688-95. doi: 10.1212/WNL.0000000000001256.DOI: 10.1212/WNL.0000000000001256
- Silberstein SD, Lipton RB, Dodick DW, Goadsby PJ, Freitag F, Mathew N, et al. Efficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial. Headache. 2007 Feb;47(2):170-80.